The antitumor efficacy of various
paclitaxel (PTX) and
docetaxel (DTX) formulations in clinical applications is seriously affected by drug resistance.
Cabazitaxel, a second-generation
taxane, exhibits greater anticancer activity than
paclitaxel and
docetaxel and has low affinity for the
P-glycoprotein (P-gp) efflux pump because of its structure. Therefore,
cabazitaxel has the potential to overcome
taxane resistance. However, owing to the high systemic toxicity and hydrophobicity of
cabazitaxel and the instability of its commercial preparation, Jevtana®, the clinical use of
cabazitaxel is restricted to patients with metastatic
castration-resistant
prostate cancer (mCRPC) who show progression after
docetaxel-based
chemotherapy. Nanomedicine is expected to overcome the limitations associated with
cabazitaxel application and surmount
taxane resistance. This review outlines the drug delivery systems of
cabazitaxel published in recent years, summarizes the challenges faced in the development of
cabazitaxel nanoformulations, and proposes strategies to overcome these challenges.